EA200500322A1 - Соединения дигидропиразолопиридина - Google Patents

Соединения дигидропиразолопиридина

Info

Publication number
EA200500322A1
EA200500322A1 EA200500322A EA200500322A EA200500322A1 EA 200500322 A1 EA200500322 A1 EA 200500322A1 EA 200500322 A EA200500322 A EA 200500322A EA 200500322 A EA200500322 A EA 200500322A EA 200500322 A1 EA200500322 A1 EA 200500322A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
present
dihydropyrazolopiridine
immunostimulants
gsk
Prior art date
Application number
EA200500322A
Other languages
English (en)
Russian (ru)
Inventor
Тосиюки Кохара
Кендзи Фукунага
Токуси Ханано
Original Assignee
Мицубиси Фарма Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мицубиси Фарма Корпорейшн filed Critical Мицубиси Фарма Корпорейшн
Publication of EA200500322A1 publication Critical patent/EA200500322A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA200500322A 2002-08-07 2003-08-01 Соединения дигидропиразолопиридина EA200500322A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002230581 2002-08-07
PCT/JP2003/009787 WO2004014910A1 (en) 2002-08-07 2003-08-01 Dihydropyrazolopyridine compounds

Publications (1)

Publication Number Publication Date
EA200500322A1 true EA200500322A1 (ru) 2005-08-25

Family

ID=31711689

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500322A EA200500322A1 (ru) 2002-08-07 2003-08-01 Соединения дигидропиразолопиридина

Country Status (14)

Country Link
EP (1) EP1537106A1 (ja)
JP (1) JP2005534713A (ja)
KR (1) KR20050069977A (ja)
CN (1) CN1675209A (ja)
AR (1) AR040961A1 (ja)
AU (1) AU2003250539A1 (ja)
BR (1) BR0313262A (ja)
CA (1) CA2494785A1 (ja)
EA (1) EA200500322A1 (ja)
IL (1) IL166482A0 (ja)
MX (1) MXPA05001434A (ja)
NO (1) NO20051153L (ja)
WO (1) WO2004014910A1 (ja)
ZA (1) ZA200501842B (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2655171C2 (ru) * 2013-04-05 2018-05-24 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Соль производного пиразолохинолина и ее кристалл
US11147803B2 (en) 2017-06-01 2021-10-19 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
US11311530B2 (en) 2017-06-01 2022-04-26 Eisai R&D Management Co., Ltd. Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
US11484502B2 (en) 2017-06-01 2022-11-01 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising PDE9 inhibitor
US11833146B2 (en) 2017-06-01 2023-12-05 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1899333T1 (sl) 2005-06-27 2009-08-31 Sanofi Aventis Pirazolopiridinski derivati kot inhibitorji kinaze 1 betaadrenergičnega receptorja
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
JP6062633B2 (ja) 2009-01-28 2017-01-18 カラ セラピューティクス インコーポレイテッド 二環式ピラゾロ複素環類
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20160096612A (ko) 2013-12-13 2016-08-16 다이이찌 산쿄 가부시키가이샤 5-하이드록시-4-(트리플루오로메틸)피라졸로피리딘 유도체
CN104140427A (zh) * 2014-07-05 2014-11-12 湖南华腾制药有限公司 一种四氢吡唑并[1,5-a]嘧啶的制备方法
CN111217754B (zh) * 2018-11-23 2023-04-07 兰州大学 一种5-氨基-4-氰基吡唑的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916140A (en) * 1988-09-28 1990-04-10 Merrell Dow Pharmaceuticals Inc. Antiepileptic pyrazolopyridines
AU4878601A (en) * 2000-04-20 2001-11-07 Mitsubishi Corporation Aromatic amide compounds
JP2005501800A (ja) * 2001-02-02 2005-01-20 三菱ウェルファーマ株式会社 ジヒドロピラゾロピリジン化合物およびその医薬用途

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2655171C2 (ru) * 2013-04-05 2018-05-24 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Соль производного пиразолохинолина и ее кристалл
US11147803B2 (en) 2017-06-01 2021-10-19 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
US11311530B2 (en) 2017-06-01 2022-04-26 Eisai R&D Management Co., Ltd. Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
US11484502B2 (en) 2017-06-01 2022-11-01 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising PDE9 inhibitor
US11833146B2 (en) 2017-06-01 2023-12-05 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Also Published As

Publication number Publication date
MXPA05001434A (es) 2005-06-06
NO20051153L (no) 2005-04-04
IL166482A0 (en) 2006-01-15
EP1537106A1 (en) 2005-06-08
WO2004014910A1 (en) 2004-02-19
JP2005534713A (ja) 2005-11-17
CN1675209A (zh) 2005-09-28
CA2494785A1 (en) 2004-02-19
BR0313262A (pt) 2005-07-12
ZA200501842B (en) 2006-05-31
AU2003250539A1 (en) 2004-02-25
AR040961A1 (es) 2005-04-27
KR20050069977A (ko) 2005-07-05

Similar Documents

Publication Publication Date Title
EA200500322A1 (ru) Соединения дигидропиразолопиридина
WO2004037181A3 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
NO20074012L (no) 1-tio-D-glucitolderivater
EA200600928A1 (ru) Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами
WO2005025554A3 (en) Dipeptidyl peptidase iv inhibitor
TW200505919A (en) DPP-IV inhibitors
WO2003002593A3 (en) Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
AU2003258621A1 (en) Novel purine derivatives, production and use thereof as medicaments
TW200504063A (en) DPP-IV inhibitors
UA94455C2 (en) Oxadiazolidinedione compound
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
WO2008011130A3 (en) Amide compounds
GEP20105033B (en) Therapeutic agent for diabetes
PT1928499E (pt) Utilização de um inibidor da dpp-iv para reduzir eventos hipoglicémicos
EA200870460A1 (ru) Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
PA8566201A1 (es) Nuevos derivados de piridina y quinolina
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
WO2010009139A3 (en) Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
ATE427926T1 (de) Cycloalkylaminderivate
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
WO2006012395A3 (en) Peptidase inhibitors
WO2004037789A3 (en) Methylene urea derivatives as raf-kinase inhibitors